{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:45:36Z","timestamp":1760820336934},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,15]],"date-time":"2011-07-15T00:00:00Z","timestamp":1310688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A breast cancer prognostic tool should ideally be applicable to all types of invasive breast lesions. A number of studies have shown histopathological grade to be an independent prognostic factor in breast cancer, adding prognostic power to nodal stage and tumour size. The Nottingham Prognostic Index has been shown to accurately predict patient outcome in stratified groups with a follow-up period of 15 years after primary diagnosis of breast cancer. Clinically, breast tumours that lack the expression of Oestrogen Receptor, Progesterone Receptor and Human Epidermal growth factor Receptor 2 (HER2) are identified as presenting a \"triple-negative\" phenotype or as triple-negative breast cancers. These poor outcome tumours represent an easily recognisable prognostic group of breast cancer with aggressive behaviour that currently lack the benefit of available systemic therapy. There are conflicting results on the prevalence of lymph node metastasis at the time of diagnosis in triple-negative breast cancer patients but it is currently accepted that triple-negative breast cancer does not metastasize to axillary nodes and bones as frequently as the non-triple-negative carcinomas, favouring instead, a preferentially haematogenous spread. Hypothetically, this particular tumour dissemination pattern would impair the reliability of using Nottingham Prognostic Index as a tool for triple-negative breast cancer prognostication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The present study tested the effectiveness of the Nottingham Prognostic Index in stratifying breast cancer patients of different subtypes with special emphasis in a triple-negative breast cancer patient subset <jats:italic>versus<\/jats:italic> non- triple-negative breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We demonstrated that besides the fact that TNBC disseminate to axillary lymph nodes as frequently as luminal or HER2 tumours, we also showed that TNBC are larger in size compared with other subtypes and almost all grade 3. Additionally, survival curves demonstrated that these prognostic factors are equally important to stratify different survival outcomes in non-TNBC as in TNBC. We also showed that the NPI retains the ability to stratify and predict survival of TNBC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The importance of this study relies on the need of prognostication improvements on TNBC, showing, at a clinical standpoint, that Nottingham Prognostic Index is as a truthful prognostic tool in TNBC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-299","type":"journal-article","created":{"date-parts":[[2011,7,15]],"date-time":"2011-07-15T18:15:53Z","timestamp":1310753753000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?"],"prefix":"10.1186","volume":"11","author":[{"given":"Andr\u00e9","family":"Albergaria","sequence":"first","affiliation":[]},{"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Milanezi","sequence":"additional","affiliation":[]},{"given":"V\u00edtor","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Amendoeira","sequence":"additional","affiliation":[]},{"given":"Daniella","family":"Vieira","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Cameselle-Teijeiro","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"issue":"2","key":"2786_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/modpathol.2010.200","volume":"24","author":"S Badve","year":"2011","unstructured":"Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011, 24 (2): 157-167. 10.1038\/modpathol.2010.200.","journal-title":"Mod Pathol"},{"issue":"1","key":"2786_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/00313020802563510","volume":"41","author":"EA Rakha","year":"2009","unstructured":"Rakha EA, Ellis IO: Triple-negative\/basal-like breast cancer: review. Pathology. 2009, 41 (1): 40-47. 10.1080\/00313020802563510.","journal-title":"Pathology"},{"issue":"1","key":"2786_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 2007, 109 (1): 25-32. 10.1002\/cncr.22381.","journal-title":"Cancer"},{"issue":"12","key":"2786_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrclinonc.2009.166","volume":"6","author":"B Weigelt","year":"2009","unstructured":"Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009, 6 (12): 718-730. 10.1038\/nrclinonc.2009.166.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2786_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/PAP.0b013e3181594733","volume":"14","author":"LK Diaz","year":"2007","unstructured":"Diaz LK, Cryns VL, Symmans WF, Sneige N: Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007, 14 (6): 419-430. 10.1097\/PAP.0b013e3181594733.","journal-title":"Adv Anat Pathol"},{"issue":"6797","key":"2786_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038\/35021093.","journal-title":"Nature"},{"issue":"16","key":"2786_CR7","doi-asserted-by":"publisher","first-page":"9212","DOI":"10.1073\/pnas.96.16.9212","volume":"96","author":"CM Perou","year":"1999","unstructured":"Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999, 96 (16): 9212-9217. 10.1073\/pnas.96.16.9212.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"2786_CR8","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98 (19): 10869-10874. 10.1073\/pnas.191367098.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2786_CR9","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100 (14): 8418-8423. 10.1073\/pnas.0932692100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"2786_CR10","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","volume":"23","author":"JD Brenton","year":"2005","unstructured":"Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol. 2005, 23 (29): 7350-7360. 10.1200\/JCO.2005.03.3845.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2786_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. Histopathology. 2008, 52 (1): 108-118.","journal-title":"Histopathology"},{"issue":"3","key":"2786_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/jcp.2005.028324","volume":"59","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Westbury C, Pierga JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006, 59 (3): 225-231. 10.1136\/jcp.2005.028324.","journal-title":"J Clin Pathol"},{"key":"2786_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2164-7-96","volume":"7","author":"Z Hu","year":"2006","unstructured":"Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006, 7: 96-10.1186\/1471-2164-7-96.","journal-title":"BMC Genomics"},{"issue":"8","key":"2786_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009, 27 (8): 1160-1167. 10.1200\/JCO.2008.18.1370.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2786_CR15","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","volume":"26","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol. 2008, 26 (15): 2568-2581. 10.1200\/JCO.2007.13.1748.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2786_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/bcr1041","volume":"7","author":"BA Gusterson","year":"2005","unstructured":"Gusterson BA, Ross DT, Heath VJ, Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005, 7 (4): 143-148. 10.1186\/bcr1041.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"2786_CR17","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/0008-5472.CAN-03-2028","volume":"64","author":"C Jones","year":"2004","unstructured":"Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, et al: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004, 64 (9): 3037-3045. 10.1158\/0008-5472.CAN-03-2028.","journal-title":"Cancer Res"},{"issue":"1","key":"2786_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr260","volume":"3","author":"SR Lakhani","year":"2001","unstructured":"Lakhani SR, O'Hare MJ: The mammary myoepithelial cell--Cinderella or ugly sister?. Breast Cancer Res. 2001, 3 (1): 1-4. 10.1186\/bcr260.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2786_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-008-0295-8","volume":"118","author":"S Nofech-Mozes","year":"2009","unstructured":"Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009, 118 (1): 131-137. 10.1007\/s10549-008-0295-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2786_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s00428-005-0010-7","volume":"447","author":"I Matos","year":"2005","unstructured":"Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F: p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005, 447 (4): 688-694. 10.1007\/s00428-005-0010-7.","journal-title":"Virchows Arch"},{"issue":"16","key":"2786_CR21","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielsen","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10 (16): 5367-5374. 10.1158\/1078-0432.CCR-04-0220.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2786_CR22","doi-asserted-by":"publisher","first-page":"214.","DOI":"10.1186\/bcr1774","volume":"9","author":"J Paredes","year":"2007","unstructured":"Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC: P-cadherin expression in breast cancer: a review. Breast Cancer Res. 2007, 9 (5): 214.-10.1186\/bcr1774.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2786_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-006-0334-y","volume":"450","author":"J Paredes","year":"2007","unstructured":"Paredes J, Lopes N, Milanezi F, Schmitt FC: P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007, 450 (1): 73-80. 10.1007\/s00428-006-0334-y.","journal-title":"Virchows Arch"},{"issue":"1","key":"2786_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1078-0432.CCR-06-1371","volume":"13","author":"K Savage","year":"2007","unstructured":"Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, et al: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007, 13 (1): 90-101. 10.1158\/1078-0432.CCR-06-1371.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2786_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-007-9718-1","volume":"110","author":"K Savage","year":"2008","unstructured":"Savage K, Leung S, Todd SK, Brown LA, Jones RL, Robertson D, James M, Parry S, Rodrigues Pinilla SM, Huntsman D, et al: Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008, 110 (2): 245-256. 10.1007\/s10549-007-9718-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"2786_CR26","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-04-2064","volume":"11","author":"JB Arnes","year":"2005","unstructured":"Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005, 11 (11): 4003-4011. 10.1158\/1078-0432.CCR-04-2064.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2786_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.anndiagpath.2007.02.004","volume":"12","author":"SM Sitterding","year":"2008","unstructured":"Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol. 2008, 12 (1): 33-40. 10.1016\/j.anndiagpath.2007.02.004.","journal-title":"Ann Diagn Pathol"},{"issue":"16","key":"2786_CR28","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-05-0059","volume":"11","author":"J Paredes","year":"2005","unstructured":"Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC: P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005, 11 (16): 5869-5877. 10.1158\/1078-0432.CCR-05-0059.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2786_CR29","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1093\/hmg\/ddq134","volume":"11","author":"A Albergaria","year":"2010","unstructured":"Albergaria A, Ribeiro AS, Pinho S, Milanezi F, Carneiro V, Sousa B, Sousa S, Oliveira C, Machado JC, Seruca R, et al: ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C\/EBP\u03b1 in CDH3 gene activation. Hum Mol Genet. 2010, 11 (13): 2554-2566.","journal-title":"Hum Mol Genet"},{"key":"2786_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(10)70008-5","volume":"11","author":"B Weigelt","year":"2010","unstructured":"Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS: Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010, 11: 339-349. 10.1016\/S1470-2045(10)70008-5.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2786_CR31","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14 (5): 1368-1376. 10.1158\/1078-0432.CCR-07-1658.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2786_CR32","doi-asserted-by":"publisher","first-page":"R4.","DOI":"10.1186\/bcr1636","volume":"9","author":"LG Fulford","year":"2007","unstructured":"Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR: Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007, 9 (1): R4.-","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2786_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/1078-0432.CCR-07-1943","volume":"14","author":"E Rakha","year":"2008","unstructured":"Rakha E, Ellis I, Reis-Filho J: Are triple-negative and basal-like breast cancer synonymous?. Clin Cancer Res. 2008, 14 (2): 618-author reply 618-619","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2786_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2559.2006.02467.x","volume":"49","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006, 49 (1): 10-21. 10.1111\/j.1365-2559.2006.02467.x.","journal-title":"Histopathology"},{"issue":"18","key":"2786_CR35","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","volume":"44","author":"WJ Irvin Jr","year":"2008","unstructured":"Irvin WJ, Carey LA: What is triple-negative breast cancer?. Eur J Cancer. 2008, 44 (18): 2799-2805. 10.1016\/j.ejca.2008.09.034.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2786_CR36","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr1771","volume":"9","author":"B Kreike","year":"2007","unstructured":"Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative\/basal-like breast carcinomas. Breast Cancer Res. 2007, 9 (5): R65-10.1186\/bcr1771.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"2786_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360 (8): 790-800. 10.1056\/NEJMra0801289.","journal-title":"N Engl J Med"},{"issue":"7","key":"2786_CR38","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1158\/1078-0432.CCR-08-2132","volume":"15","author":"EA Rakha","year":"2009","unstructured":"Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009, 15 (7): 2302-2310. 10.1158\/1078-0432.CCR-08-2132.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2786_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","volume":"115","author":"R Dent","year":"2009","unstructured":"Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009, 115 (2): 423-428. 10.1007\/s10549-008-0086-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"2786_CR40","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13 (15): 4429-4434. 10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"2786_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2407-7-134","volume":"7","author":"M Tischkowitz","year":"2007","unstructured":"Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007, 7: 134-10.1186\/1471-2407-7-134.","journal-title":"BMC Cancer"},{"issue":"9","key":"2786_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","volume":"30","author":"DG Hicks","year":"2006","unstructured":"Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, et al: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006, 30 (9): 1097-1104.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2786_CR43","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1078-0432.CCR-05-2281","volume":"12","author":"SM Rodriguez-Pinilla","year":"2006","unstructured":"Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006, 12 (5): 1533-1539. 10.1158\/1078-0432.CCR-05-2281.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2786_CR44","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0046-8177(99)90028-X","volume":"30","author":"H Tsuda","year":"1999","unstructured":"Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S: Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol. 1999, 30 (10): 1134-1139. 10.1016\/S0046-8177(99)90028-X.","journal-title":"Hum Pathol"},{"issue":"2","key":"2786_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12253-008-9067-3","volume":"14","author":"AH Lee","year":"2008","unstructured":"Lee AH, Ellis IO: The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res. 2008, 14 (2): 113-115. 10.1007\/s12253-008-9067-3.","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"2786_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/modpathol.3800114","volume":"17","author":"DV Miller","year":"2004","unstructured":"Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, et al: Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol. 2004, 17 (7): 756-764. 10.1038\/modpathol.3800114.","journal-title":"Mod Pathol"},{"issue":"3","key":"2786_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF01840834","volume":"22","author":"MH Galea","year":"1992","unstructured":"Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992, 22 (3): 207-219. 10.1007\/BF01840834.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2786_CR48","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0959-8049(99)00056-8","volume":"35","author":"J Kollias","year":"1999","unstructured":"Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW: The prognosis of small primary breast cancers. Eur J Cancer. 1999, 35 (6): 908-912. 10.1016\/S0959-8049(99)00056-8.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2786_CR49","first-page":"963","volume":"25","author":"B Sousa","year":"2010","unstructured":"Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, Vieira D, Albergaria A, Veronese L, Carneiro V, et al: P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol. 2010, 25 (8): 963-974.","journal-title":"Histol Histopathol"},{"issue":"3","key":"2786_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1055-9965.EPI-06-0806","volume":"16","author":"XR Yang","year":"2007","unstructured":"Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007, 16 (3): 439-443. 10.1158\/1055-9965.EPI-06-0806.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"21","key":"2786_CR51","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1002\/cncr.24573","volume":"115","author":"R Dent","year":"2009","unstructured":"Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer. 2009, 115 (21): 4917-4923. 10.1002\/cncr.24573.","journal-title":"Cancer"},{"issue":"20","key":"2786_CR52","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 2010, 363 (20): 1938-1948. 10.1056\/NEJMra1001389.","journal-title":"N Engl J Med"},{"issue":"9","key":"2786_CR53","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007, 109 (9): 1721-1728. 10.1002\/cncr.22618.","journal-title":"Cancer"},{"issue":"5","key":"2786_CR54","doi-asserted-by":"publisher","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","volume":"7","author":"FM Blows","year":"2010","unstructured":"Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7 (5): e1000279-10.1371\/journal.pmed.1000279.","journal-title":"PLoS Med"},{"issue":"4","key":"2786_CR55","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/annonc\/mdn675","volume":"20","author":"A Spitale","year":"2009","unstructured":"Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A: Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009, 20 (4): 628-635. 10.1093\/annonc\/mdn675.","journal-title":"Ann Oncol"},{"issue":"1","key":"2786_CR56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10549-008-0102-6","volume":"117","author":"WD Foulkes","year":"2008","unstructured":"Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO: Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat. 2008, 117 (1): 199-204.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-299\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:59:37Z","timestamp":1630616377000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2786"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-299","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,15]]},"assertion":[{"value":"4 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"299"}}